{"id":1936,"date":"2026-05-02T05:33:22","date_gmt":"2026-05-02T05:33:22","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/05\/02\/aan-2026-diabetes-weight-loss-drug-associated-with-benefit\/"},"modified":"2026-05-02T05:33:22","modified_gmt":"2026-05-02T05:33:22","slug":"aan-2026-diabetes-weight-loss-drug-associated-with-benefit","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/05\/02\/aan-2026-diabetes-weight-loss-drug-associated-with-benefit\/","title":{"rendered":"AAN 2026 Diabetes\/Weight Loss Drug associated with Benefit"},"content":{"rendered":"
Tweet<\/a><\/div>\n

I suspect we will see lots of studies on the influence of GLP-1 inhibitors on all sorts of conditions they have been approved for type II diabetes treatment and are commonly used to lose weight. It has now been approved for use in UK for heart related effects and if you lose weight you may be motivated to help keep it off with abit more excercise. This is what has been observed in this study in people with MS.<\/p>\n

GLP-1 Receptor Agonist Use Associated With Greater Physical Activity and Improved Patient-reported Outcomes in Multiple Sclerosis: A Single-site Retrospective Cohort Study<\/p>\n

Karl Heward1<\/sup>, Gloria Hou2<\/sup>, Sarah Simmons2<\/sup>, Edward Kim1<\/sup>, Michael Persenaire1<\/sup>, Evan Madill1<\/sup>, Yujie Wang1<\/sup>, Gloria Von Geldern1<\/sup>, Annette Wundes1<\/sup>, Shuvro Roy11<\/sup>Department of Neurology, 2<\/sup>Department of Rehabilitation Medicine, University of Washington, Seattle, WA<\/p>\n

Objective: To assess whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with changes in exercise activity and patient-reported outcomes (PROs) in people with multiple sclerosis (MS).<\/p>\n

Background:GLP-1\u00a0RAs,\u00a0used for type 2 diabetes and obesity, have\u00a0plausible\u00a0central nervous system\u00a0effects\u00a0on\u00a0neuroinflammation, energy, balance, fatigue,\u00a0and\u00a0mood, which\u00a0may influence MS symptoms\u00a0and improve\u00a0physical activity.<\/p>\n

Design\/Methods: We conducted a retrospective observational cohort study of MS patients treated with GLP-1 RA\u2019s. Pharmacy and medication administration records identified GLP-1 RA initiation dates. We extracted self-reported physical activity (minutes\/week of moderate-to-vigorous physical activity) and SymptoMScreen PROs, (13 domains, 0\u20136 scale) collected routinely during visits at the last MS center visit prior to initiation and compared to visits \u22656 months after. Patients without data for either visit were excluded; those treated with multiple GLP-1 RAs were included only for their first exposure. Paired within-person comparisons assessed pre- and post-exposure changes.<\/p>\n

Results:Seventy patients were included (mean age 51.3 years, 87% female, median EDSS 2.5 [IQR 1.0\u20134.5]). Follow-up visits were 7.2 months (218 days) after initiation of GLP-1 RA on average. Physical activity increased from 52.3 to 115.7 minutes\/week after GLP-1RA initiation (mean change +65.8, 95% CI +48.5 to +83.0, p<0.001).<\/strong> Significant improvements were observed in anxiety (\u20130.65), bowel dysfunction (\u20130.52), bladder dysfunction (\u20130.64), and sensory symptoms (\u20130.54), all p<0.001. Smaller but significant improvements noted in body pain (\u20130.48, p=0.004), vision (\u20130.31, p=0.04), spasticity (\u20130.28, p=0.03), and dizziness (\u20130.39, p=0.02). No significant changes were seen in walking, hand function, fatigue, cognition, or depression.<\/p>\n

Conclusions: GLP-1\u00a0RA initiation\u00a0in MS was associated with\u00a0greater\u00a0physical\u00a0activity and improvements in several\u00a0PRO\u00a0domains,\u00a0further\u00a0supporting\u00a0association of\u00a0metabolic health\u00a0with\u00a0MS outcomes and\u00a0need for prospective studies to\u00a0validate\u00a0these findings.<\/p>\n

Source: multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Tweet I suspect we will see lots of studies on the influence of GLP-1 inhibitors on all sorts of conditions they have been approved for type II diabetes treatment and are commonly used to lose weight. It has now been approved for use in UK for heart related effects and if you lose weight you…<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1936","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1936"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1936\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}